drugset

drugset / Trial / NCT01281631

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT01281631 ↗

Phase 2 Completed 136 enrolled Neuraltus Pharmaceuticals, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study of NP001 in subjects with ALS.

Timeline

Start: 2011-02
Primary completion: 2012-09
Completion: 2012-09

Publications

Forrest BD, Goyal NA, Fleming TR, Bracci PM, Brett NR, Khan Z, Robinson M, Azhir A, McGrath M. The Effectiveness of NP001 on the Long-Term Survival of Patients with Amyotrophic Lateral Sclerosis. Biomedicines. 2024 Oct 16;12(10):2367. doi: 10.3390/biomedicines12102367.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NP001	Unknown	1 mg/kg	Intravenous
Subject	NP001	Unknown	2 mg/kg	Intravenous

Indications